Energetic and Dynamic Aspects of the Affinity Maturation Process: Characterizing Improved Variants from the Bevacizumab Antibody with Molecular Simulations

被引:15
作者
Corrada, Dario [1 ]
Colombo, Giorgio [1 ]
机构
[1] CNR, ICRM, I-20131 Milan, Italy
关键词
ENDOTHELIAL GROWTH-FACTOR; CRYSTAL-STRUCTURE; PROTEIN DYNAMICS; MONOCLONAL-ANTIBODY; ANGSTROM RESOLUTION; ANTIGEN COMPLEXES; COMBINING SITE; VEGF ANTIBODY; BINDING; STABILITY;
D O I
10.1021/ci400416e
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Antibody affinity maturation is one of the fundamental processes of immune defense against invading pathogens. From the biological point of view, the clonal selection hypothesis represents the most accepted mechanism to explain how mutations increasing the affinity for target antigens are introduced and selected in antibody molecules. However, understanding at the molecular level how protein modifications, such as point mutation, can modify and modulate the affinity of an antibody for its antigen is still a major open issue in molecular biology. In this paper, we address various aspects of this problem by analyzing and comparing atomistic simulations of 17 variants of the bevacizumab antibody, all directed against the common target protein VEGF-A. In particular, we examine MD-based descriptors of the internal energetics and dynamics of mutated antibodies and their possible correlations with experimentally determined affinities for the antigens. Our results show that affinity improvement is correlated with a variation of the internal stabilization energy of the antibody molecule when bound to the antigen, compensated by the variation in the interaction energy between the antigen and the antibody, paralleled by an overall modulation of internal coordination within the antibody molecular structure. A possible model of the mechanism of rigidification and of the main residues involved is proposed. Overall, our results can help in understanding the molecular determinants of antigen recognition and have implications in the rational design of new antibodies with optimized affinities.
引用
收藏
页码:2937 / 2950
页数:14
相关论文
共 57 条
[1]   Analysis and improvements to Kabat and structurally correct numbering of antibody variable domains [J].
Abhinandan, K. R. ;
Martin, Andrew C. R. .
MOLECULAR IMMUNOLOGY, 2008, 45 (14) :3832-3839
[2]   Protein Dynamics and the Diversity of an Antibody Response [J].
Adhikary, Ramkrishna ;
Yu, Wayne ;
Oda, Masayuki ;
Zimmermann, Joerg ;
Romesberg, Floyd E. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (32) :27139-27147
[3]   Selection and analysis of an optimized anti-VEGF antibody: Crystal structure of an affinity-matured Fab in complex with antigen [J].
Chen, Y ;
Wiesmann, C ;
Fuh, G ;
Li, B ;
Christinger, HW ;
McKay, P ;
de Vos, AM ;
Lowman, HB .
JOURNAL OF MOLECULAR BIOLOGY, 1999, 293 (04) :865-881
[4]   Design of therapeutic proteins with enhanced stability [J].
Chennamsetty, Naresh ;
Voynov, Vladimir ;
Kayser, Veysel ;
Helk, Bernhard ;
Trout, Bernhardt L. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (29) :11937-11942
[5]   Similar folds with different stabilization mechanisms: the cases of prion and doppel proteins [J].
Colacino, Stefano ;
Tiana, Guido ;
Colombo, Giorgio .
BMC STRUCTURAL BIOLOGY, 2006, 6
[6]   Investigating Allostery in Molecular Recognition: Insights from a Computational Study of Multiple Antibody-Antigen Complexes [J].
Corrada, Dario ;
Morra, Giulia ;
Colombo, Giorgio .
JOURNAL OF PHYSICAL CHEMISTRY B, 2013, 117 (02) :535-552
[7]   How antibodies fold [J].
Feige, Matthias J. ;
Hendershot, Linda M. ;
Buchner, Johannes .
TRENDS IN BIOCHEMICAL SCIENCES, 2010, 35 (04) :189-198
[8]   An Unfolded CH1 Domain Controls the Assembly and Secretion of IgG Antibodies [J].
Feige, Matthias J. ;
Groscurth, Sandra ;
Marcinowski, Moritz ;
Shimizu, Yuichiro ;
Kessler, Horst ;
Hendershot, Linda M. ;
Buchner, Johannes .
MOLECULAR CELL, 2009, 34 (05) :569-579
[9]   Entropy-enthalpy transduction caused by conformational shifts can obscure the forces driving protein-ligand binding [J].
Fenley, Andrew T. ;
Muddana, Hari S. ;
Gilson, Michael K. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (49) :20006-20011
[10]   Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer [J].
Ferrara, N ;
Hillan, KJ ;
Gerber, HP ;
Novotny, W .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (05) :391-400